

**Proxy Statement Pursuant to Section 14(a)  
of the Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to Rule 14a-11(c) or rule 14a-12

**OPGEN, INC.**

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.**
  - Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
    - (1) Title of each class of securities to which transaction applies:
    - (2) Aggregate number of securities to which transaction applies:
    - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11:
    - (4) Proposed maximum aggregate value of transaction:
    - (5) Total fee paid:
  - Fee paid previously with preliminary materials:
  - Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
    - (1) Amount previously paid:
    - (2) Form, Schedule or Registration Statement no.:
    - (3) Filing Party:
    - (4) Date Filed:
-



708 Quince Orchard Road, Suite 205  
Gaithersburg, MD 20878

**2017 ANNUAL MEETING OF STOCKHOLDERS  
TO BE HELD ON JUNE 8, 2017**

June 6, 2017

On June 6, 2017, Laurence R. McCarthy, Ph.D., a director of OpGen, Inc. (the "Company") since 2013, notified the Company that he had determined not to seek re-election as a director of the Company because of other professional commitments. There was no disagreement between Dr. McCarthy and the Company leading to the decision. Dr. McCarthy's term as a director will end at the 2017 Annual Meeting of Stockholders on June 8, 2017.

Any proxies voted with respect to Dr. McCarthy's nomination as a director will not be voted by the proxy holders identified in the proxy statement. As of the date of the Annual Meeting, the number of directors shall be six. All other nominees for director identified in the proxy statement are standing for re-election.